Dexcom Raises Another Billion, But Why?

The company’s cash balance at the end of last quarter was more than enough to weather most storms – so why has Dexcom raised more money?  

Will Dexcom be spending big in the near future? • Source: Shutterstock

Continuous glucose monitor manufacturer Dexcom has announced plans to raise a total of $1.1bn via issuance of senior convertible notes at an interest rate of 0.375%.

A senior convertible note is a type of debt security that provides buyers with the option to convert their note into a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Medtech Insight

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.